

◆ Department of Continuing Medical Education ◆

Conflict of Interest Disclosure and Resolution & Core Competencies

Third Annual ISSPP Congress 2022

October 13-14, 2022

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Prasad S. Adusumilli, MD	Grant/Research Support from Atara Biotherapeutics; Consultant for Atara Biotherapeutics, Bayer, BioArdis, Imugene, and Johnson & Johnson.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Mohammad Alyami, MD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Cisplatin and Doxorubicin</i>	1, 2, 3, 4, 5 & 6
Brian Badgwell, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None	1
Naoual Bakrin, MD, PhD	Consultant for GlaxoSmithKline.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Cisplatin and Doxorubicin</i>	1, 2 & 4
Lana Bijelic, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Wilbur Bo Bowne, MD	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 4

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Andreas Brandl, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	Delphi Results
Wim P. Ceelen, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Abraxane, & OniVyde</i>	2 & 4
Joseph Chao, MD	Grant/Research Support from Merck; Consultant for Amgen, Astellas, AstraZeneca, Merck, and Roche; On the Speakers Bureau for Bristol Myers Squibb, and Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Ernest Cheng, MD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Bromelain and N-acetylcysteine</i>	2 & 4
Vincent Chung, MD	On the Speakers Bureau for AstraZeneca, and Ipsen; Consultant for Pfizer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Delia Cortés-Guiral, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 4
Thanh H. Dellinger, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Planner/Moderator
Jesse Demuytere, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Danielle K. DePeralta, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Jacopo Desiderio, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Sönke Detlefsen, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4
Jesus Esquivel, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2 & 4
Clarisse Eveno, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Marwan G. Fakih, MD	Consultant for Amgen, AstraZeneca, Bayer, GlaxoSmithKline, Mirati Therapeutics, Pfizer, PsiOxus Therapeutics, Roche/Genentech, and Taiho Oncology; On the Speakers Bureau for Guardant 360.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Kjersti Flatmark, MD, PhD	Grant/Research Support from Bayer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 4
Christina Fotopoulou, MD, PhD	Consultant for AstraZeneca, Ethicon, GlaxoSmithKline, MSD, Roche, and Tesaro.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Alexandra Gangi, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Olivier Glehen, MD, PhD	Consultant for Gamida Cell.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 4 & 5

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Céline Gongora, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Martin Graversen, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Travis E. Grotz, MD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Cisplatin, Mitomycin C, Nab-paclitaxel</i>	1, 2 & 4
Martin Hübner, MD	Grant from Capnomed; Consultant for Encare.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 4 & 6
Hironori Ishigami, MD, PhD	Grant/Research Support from Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co, Ltd.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Paclitaxel</i>	1, 2 & 4
Pashtoon Kasi, MD, MS	Consultant for Bayer, Daiichi Sankyo, Inc., Eisai, Exact Sciences, Foundation Medicine, Lilly, Merck, Natera, Servier, and Taiho Pharmaceutical Co, Ltd.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Samuel J. Klempner, MD	Consultant for AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, and Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2 & 4
Robert S. Krouse, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4 & 5
Ulrich M. Lauer, MD	Consultant for Amgen, Ipsen, & ViraTherapeutics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: OLVI-VEC (formerly denominated as GL-ONC1) (Genelux, San Diego, CA)</i>	1, 2, 4 & 6
Edward A. Levine, MD	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 4
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator & Reviewer
Faheez Mohamed, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Amit Merchea, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Michael Bau Mortensen, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 2
I. Benjamin Paz, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Marc Pocard, MD, PhD	Grant/Research Support from Bristol Myers Squibb, CAPNOMED GmbH, and Pierre Fabre; Consultant for Gamida, LEO Pharm, and Roche.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6 Plenary Abstract

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Saul Priceman, PhD	Consultant for Celularity, Imugene, and Mustang Bio.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: CAR T Cells</i>	4
Robert Ramsay, PhD	Grant/Research Support from Merck.	Attestation on file – No conflict noted	Moderator
Mustafa Raouf, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Mitomycin C, Abraxane (Nab-Paclitaxel), Oxaliplatin, 5-FU, Cisplatin, Doxorubicin</i>	1, 3 & 4 Planner/Faculty
Pascal Rousset, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1
Camilla Row	I do not have any relevant financial relationships with any ineligible companies.	None	Patient
Valerie W. Rusch, MD	Grant/Research Support from Genentech.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Somashekhar S P, MCh	I do not have any relevant financial relationships with any ineligible companies.	None	1, 3 & 4
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner
Hooman Salavati, MSc	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Ravi Salgia, MD, PhD	Consultant for AstraZeneca and Sanofi; On the Speakers Bureau for AstraZeneca and Sanofi.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: CAR T Cells</i>	1, 2, 3, 4, 5 & 6
Olivia Sgarbura, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Cisplatin Doxorubicin as PIPAC Immunotherapy for MPM</i>	1, 2, 4, 5 & 6
Jimmy B.Y. So, MBChB, MPH	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Wiebke Solass, MD	I do not have any relevant financial relationships with any ineligible companies.	None	4 Plenary Abstract
Daphne Stewart, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Beatrice Sun, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Virginia Sun, PhD, RN	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 5
Raghav Sundar, MBBS, PhD	Grant/Research Support from MSD; Consultant for Bayer, Bristol Myers Squibb, Eisai, Merck, and MSD.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4
Senthil Sundaram, BS	I do not have any relevant financial relationships with any ineligible	None	Patient

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Kiran K. Turaga MD, MPH	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Erena van der Heijden	I do not have any relevant financial relationships with any ineligible companies.	None	Patient
Willemien J. van Driel, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 2
Konstantinos Votanopoulos, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Richard L. Whelan, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Yanghee Woo, MD	I do not have any relevant financial relationships with any ineligible companies	<i>None Off-label/Investigational use of: Oncolytic Viruses, and CAR-T Cell in clinical trials</i>	1, 3 & 4 Planner/ Faculty
Wei Peng Yong, MBChB	On the Speakers Bureau for Bristol Myers Squibb, Eisai, Lilly, and MSD; Consultant for Amgen, and AstraZeneca.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Paclitaxel, 5FV, Oxaliplatin, Asplatin</i>	2, 3 & 4

CME Committee	Commercial Interest	Conflict/ Resolution	Role
Patricia Aoun, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Chandana Banerjee, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer/Moderator
Anna Pawlowska, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Michael Rosenzweig, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Behrouz Salehian, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Gagandeep Singh, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Sepidah Shayani, PharmD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer

Shanmuga Subbiah, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
----------------------	---	------	----------

1. The ACCME defines "relevant" financial relationships" as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an "Ineligible company" as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.